Inventor
LING LEI
US38 patents
⚠️ This page may combine multiple inventors who share the name “LING LEI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NGM BIOPHARMACEUTICALS INC
26 patentsUS9751924B2Sep 5, 2017
Methods of using compositions comprising fusion variants of FGF19 polypeptides for reducing glucose levels in a subject
NGM BIOPHARMACEUTICALS INC32 citations98
US9670260B2Jun 6, 2017
Compositions comprising fusion variants of FGF19 polypeptides
NGM BIOPHARMACEUTICALS INC34 citations98
US9580483B2Feb 28, 2017
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of diabetes
NGM BIOPHARMACEUTICALS INC36 citations98
US9273107B2Mar 1, 2016
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
NGM BIOPHARMACEUTICALS INC36 citations98
US9089525B1Jul 28, 2015
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
NGM BIOPHARMACEUTICALS INC37 citations98
US9974833B2May 22, 2018
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having pregnancy intrahepatic cholestasis
NGM BIOPHARMACEUTICALS INC19 citations94
US9963494B2May 8, 2018
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
NGM BIOPHARMACEUTICALS INC19 citations94
US9925242B2Mar 27, 2018
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis
NGM BIOPHARMACEUTICALS INC25 citations94
US9895416B2Feb 20, 2018
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having cholestasis
NGM BIOPHARMACEUTICALS INC25 citations94
US9889177B2Feb 13, 2018
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having primary sclerosing cholangitis
NGM BIOPHARMACEUTICALS INC25 citations94
US9889178B2Feb 13, 2018
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having nonalcoholic steatohepatitis
NGM BIOPHARMACEUTICALS INC25 citations94
US9878009B2Jan 30, 2018
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having error of bile acid synthesis
NGM BIOPHARMACEUTICALS INC25 citations94
US9878008B2Jan 30, 2018
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having bile acid diarrhea or bile acid malabsorption
NGM BIOPHARMACEUTICALS INC26 citations94
US9290557B2Mar 22, 2016
Compositions comprising variants and fusions of FGF19 polypeptides
NGM BIOPHARMACEUTICALS INC37 citations94
US10413590B2Sep 17, 2019
Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject
NGM BIOPHARMACEUTICALS INC10 citations92
US10744185B2Aug 18, 2020
Methods of using variants of FGF19 polypeptides for the treatment of pruritus
NGM BIOPHARMACEUTICALS INC7 citations84
US10456449B2Oct 29, 2019
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
NGM BIOPHARMACEUTICALS INC10 citations84
US10398758B2Sep 3, 2019
Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
NGM BIOPHARMACEUTICALS INC9 citations84
US10369199B2Aug 6, 2019
Methods of using variants of FGF19 polypeptides for the treatment of cancer
NGM BIOPHARMACEUTICALS INC9 citations84
US11564972B2Jan 31, 2023
Methods of using compositions comprising variants of FGF19 polypeptides for treating primary biliary cirrhosis in a subject
NGM BIOPHARMACEUTICALS INC0 citations63
US11370841B2Jun 28, 2022
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
NGM BIOPHARMACEUTICALS INC0 citations63
US11241481B2Feb 8, 2022
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
NGM BIOPHARMACEUTICALS INC1 citations63
US11103554B2Aug 31, 2021
Methods of using compositions comprising variants of FGF19 polypeptides for reducing bile acid synthesis in a subject having cirrhosis
NGM BIOPHARMACEUTICALS INC0 citations63
US11065302B2Jul 20, 2021
Compositions comprising fusion variants of FGF19 polypeptides
NGM BIOPHARMACEUTICALS INC0 citations62
US11066454B2Jul 20, 2021
Compositions comprising variants and fusions of FGF19 polypeptides
NGM BIOPHARMACEUTICALS INC0 citations62
US10758590B2Sep 1, 2020
Methods of using compositions comprising variants and fusions of FGF 19 polypeptides for treating diabetes
NGM BIOPHARMACEUTICALS INC0 citations52
FX LIFE SCIENCES INTERNAT GMBH
3 patentsUS7413756B2Aug 19, 2008
Processes of making north american ginseng fractions, products containing them, and use as immunomodulators
FX LIFE SCIENCES INTERNAT GMBH12 citations90
US7186423B2Mar 6, 2007
Processes of making North American ginseng fractions, products containing them, and uses as immunomodulators
FX LIFE SCIENCES INTERNAT GMBH12 citations90
US7195783B2Mar 27, 2007
Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics
FX LIFE SCIENCES INTERNAT GMBH12 citations79
C V TECHNOLOGIES INC
2 patentsUS6432454B1Aug 13, 2002
Processes of making north american ginseng fractions, products containing them, and use as immunomodulators
C V TECHNOLOGIES INC27 citations90
US7067160B2Jun 27, 2006
Processes of making North American ginseng fractions, products containing them, and use as immunomodulators
C V TECHNOLOGIES INC8 citations71